1. Home
  2. ADNT vs NBTX Comparison

ADNT vs NBTX Comparison

Compare ADNT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$18.89

Market Cap

1.5B

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$21.78

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADNT
NBTX
Founded
2016
2003
Country
Ireland
France
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ADNT
NBTX
Price
$18.89
$21.78
Analyst Decision
Hold
Strong Buy
Analyst Count
9
1
Target Price
$22.11
$8.00
AVG Volume (30 Days)
1.3M
52.9K
Earning Date
11-05-2025
09-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,535,000,000.00
$11,930,711.00
Revenue This Year
$0.98
N/A
Revenue Next Year
$2.62
$122.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.04
$2.76
52 Week High
$26.16
$30.35

Technical Indicators

Market Signals
Indicator
ADNT
NBTX
Relative Strength Index (RSI) 39.42 55.80
Support Level $18.76 $20.05
Resistance Level $19.76 $21.63
Average True Range (ATR) 0.79 1.09
MACD 0.11 -0.01
Stochastic Oscillator 39.49 65.91

Price Performance

Historical Comparison
ADNT
NBTX

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: